SCHEMBL30714740

SCHEMBL30714740

Cn1nc2ccc(OCC3CC3)cc2c1C(=O)NCCNS(C)(=O)=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MTNR1A P48039 1/20 0.43
▸ SCN9A Q15858 4/20 0.40
▸ GSK3B P49841 1/20 0.40
▸ ADAM17 P78536 1/20 0.36
▸ MALT1 Q9UDY8 1/20 0.36
▸ ITGB3 P05106 1/20 0.35
▸ ITGA2B P08514 1/20 0.35
▸ PARP15 Q460N3 1/20 0.35
▸ PARP10 Q53GL7 1/20 0.35
▸ ACACB O00763 2/20 0.35
▸ KDR P35968 1/20 0.35
▸ HTR4 Q13639 2/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ NFKB1 P19838 1/20 0.35
▸ PMP22 Q01453 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ KCNH2 Q12809 1/20 0.35
▸ IRAK4 Q9NWZ3 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30714619 0.85 KDM4E (0.43) MTNR1AGSK3BPARP15PARP10ACACB
SCHEMBL31539906 0.79 PDE4A (0.38) SCN9AHTR4CYP1A2CYP2C9ALOX15
SCHEMBL31539879 0.78 PARP10 (0.49) MTNR1APARP15PARP10ACACB
SCHEMBL30714681 0.78 CNR2 (0.43) MTNR1ASCN9APARP15PARP10ACACB
SCHEMBL30714578 0.77 ACACB (0.43) PARP15PARP10ACACBCYP2C9
SCHEMBL30714718 0.77 ACACB (0.43) PARP15PARP10ACACBCYP2C9
SCHEMBL30714577 0.77 PARP10 (0.39) MTNR1ASCN9APARP15PARP10ACACB
SCHEMBL30714562 0.76 CNR2 (0.41) ACACB
SCHEMBL30714621 0.76 CNR2 (0.41) ACACB
SCHEMBL30714637 0.75 ACACB (0.42) PARP15PARP10ACACBCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 — — US disclosed
EP-4499624-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 — — EP disclosed
WO-2023230540-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS TRPV3, TRPM2, TRPV1 MTNR1A 115/4885SCN9A 518/4885GSK3B 1306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback